We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
Read MoreHide Full Article
DiaMedica Therapeutics Inc. (DMAC - Free Report) announced that it initiated a pivotal phase II/III study — ReMEDy2 — to evaluate its recombinant kallikrein-1 (KLK1) protein candidate, DM199, as a potential treatment of acute ischemic stroke (AIS). Data from this study will support a biologics license application for the candidate.
The study will evaluate the administration of the candidate within 24 hours of the onset of AIS symptoms compared to placebo for two primary endpoints — improvement in recovery after a stroke and prevention of stroke recurrence. The recovery from stroke will be measured by the well-established modified Rankin Scale. The company is evaluating an intravenous as well as a subcutaneous formulation of the candidate.
The study will not include participants who have undergone tissue plasminogen activator (tPA) and those with large vessel occlusions.
Data from the phase II ReMEDy study demonstrated improvement in stroke outcomes and reduction in stroke recurrence following treatment of AIS with DM199. The candidate also demonstrated an excellent safety profile in the study.
Shares of DiaMedica have declined 61.1% so far this year against the industry’s increase of 0.8%.
Image Source: Zacks Investment Research
The company believes that DM199 can meaningfully change the outcomes in AIS patients as it will provide flexibility of a 24-hour treatment window for this emergency compared to the currently much smaller 4.5 hours treatment window for tPA. The longer treatment window is also likely to increase the eligible patient population for DM199. Successful development DM199 can prove to be beneficial for almost 80% of patients who have suffered an AIS and have no treatment option available currently.
Per the press release, there are approximately 795,000 cases of ischemic or hemorrhagic stroke annually in the United States. Almost three-fourths of the cases are first event and the rest represents recurrent strokes. Apart from the United States, millions of strokes occurrences happen globally every year. This represents a significant opportunity for DM199, if developed successfully in the pivotal study, followed by a potential approval due to high unmet need.
Apart from AIS, DiaMedica is also evaluating the subcutaneous formulation of the candidate in the phase II REDUX study as a potential treatment for chronic kidney disease. Interim data announced in June demonstrated that treatment with DM199 led to clinically meaningful improvements in kidney function.
Meanwhile, a few other pharma/biotech companies are developing treatments for AIS which include AbbVie’s (ABBV - Free Report) elezanumab, Biogen’s (BIIB - Free Report) TMS-007, and Pfizer’s (PFE - Free Report) mono-drug therapy in combination with an oral anticoagulant
Image: Bigstock
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
DiaMedica Therapeutics Inc. (DMAC - Free Report) announced that it initiated a pivotal phase II/III study — ReMEDy2 — to evaluate its recombinant kallikrein-1 (KLK1) protein candidate, DM199, as a potential treatment of acute ischemic stroke (AIS). Data from this study will support a biologics license application for the candidate.
The study will evaluate the administration of the candidate within 24 hours of the onset of AIS symptoms compared to placebo for two primary endpoints — improvement in recovery after a stroke and prevention of stroke recurrence. The recovery from stroke will be measured by the well-established modified Rankin Scale. The company is evaluating an intravenous as well as a subcutaneous formulation of the candidate.
The study will not include participants who have undergone tissue plasminogen activator (tPA) and those with large vessel occlusions.
Data from the phase II ReMEDy study demonstrated improvement in stroke outcomes and reduction in stroke recurrence following treatment of AIS with DM199. The candidate also demonstrated an excellent safety profile in the study.
Shares of DiaMedica have declined 61.1% so far this year against the industry’s increase of 0.8%.
Image Source: Zacks Investment Research
The company believes that DM199 can meaningfully change the outcomes in AIS patients as it will provide flexibility of a 24-hour treatment window for this emergency compared to the currently much smaller 4.5 hours treatment window for tPA. The longer treatment window is also likely to increase the eligible patient population for DM199. Successful development DM199 can prove to be beneficial for almost 80% of patients who have suffered an AIS and have no treatment option available currently.
Per the press release, there are approximately 795,000 cases of ischemic or hemorrhagic stroke annually in the United States. Almost three-fourths of the cases are first event and the rest represents recurrent strokes. Apart from the United States, millions of strokes occurrences happen globally every year. This represents a significant opportunity for DM199, if developed successfully in the pivotal study, followed by a potential approval due to high unmet need.
Apart from AIS, DiaMedica is also evaluating the subcutaneous formulation of the candidate in the phase II REDUX study as a potential treatment for chronic kidney disease. Interim data announced in June demonstrated that treatment with DM199 led to clinically meaningful improvements in kidney function.
Meanwhile, a few other pharma/biotech companies are developing treatments for AIS which include AbbVie’s (ABBV - Free Report) elezanumab, Biogen’s (BIIB - Free Report) TMS-007, and Pfizer’s (PFE - Free Report) mono-drug therapy in combination with an oral anticoagulant
DiaMedica Therapeutics, Inc. Price
DiaMedica Therapeutics, Inc. price | DiaMedica Therapeutics, Inc. Quote
Zacks Rank
DiaMedica currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.